Sarepta Therapeutics has completed the submission of the casimersen NDA for the treatment of DMD in patients who have genetic mutations that are amenable to skipping exon 45 of the Duchenne gene.
Among patients with permanent atrial fibrillation, cognitive impairment may be more common in those with suboptimal antithrombotic therapy, oral anticoagulation, or heart rate control.
Positive topline data was announced from the phase 3 ADAPT trial of efgartigimod (ARG-113; argenx) in adult patients with generalized myasthenia gravis.
The FDA has approved solifenacin succinate LS oral suspension for the treatment of neurogenic detrusor overactivity in pediatric patients 2 years of age and older.
Higher cardiovascular risk burden assessed by the Framingham General Cardiovascular Risk Score is associated with cognitive decline and structural brain differences.
The International Myasthenia Gravis/COVID-19 Working Group has published a short guidance statement on the management of MG and Lambert-Eaton myasthenic syndrome during this novel pandemic.
